<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2101256697
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Wegovy
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEMAGLUTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1155.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 445]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novo Nordisk
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BJ06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Wegovy&reg; is</p><p>Wegovy&reg; is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. It works by acting on targets (receptors) in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight.</p><p><strong>&nbsp;</strong></p><p>What Wegovy&reg; is used for</p><p>Wegovy&reg; is used together with diet and physical activity for weight loss and to help keep the weight under control. It is used in adults, who have</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a BMI of 30 kg/m&sup2; or greater (obesity) or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a BMI of at least 27 kg/m&sup2; but less than 30 kg/m&sup2; (overweight) who have weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called &lsquo;obstructive sleep apnoea&rsquo; or a history of heart attack, stroke or blood vessel problems).</p><p>&nbsp;</p><p>BMI (Body Mass Index) is a measure of your weight in relation to your height.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Wegovy&reg;&nbsp;</p><p>&bull; if you are allergic to semaglutide or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Wegovy&reg;.&nbsp;</p><p>&nbsp;</p><p>The use of Wegovy&reg; is not recommended if you:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use other products for weight loss,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have type 1 diabetes,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severely reduced kidney function,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severely reduced liver function,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe heart failure,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have diabetic eye disease (retinopathy).</p><p>&nbsp;</p><p>There is little experience with Wegovy&reg; in patients:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of 75 years and older,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with liver problems,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.</p><p>&nbsp;</p><p>Please consult your doctor if one of the above applies to you.</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration</p><p>During treatment with Wegovy&reg;, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas</p><p>If you have severe and on-going pain in the stomach area (see section 4) &ndash; see a doctor straight away as this could be a sign of inflamed pancreas (acute pancreatitis).</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People with type 2 diabetes</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wegovy&reg; cannot be used as a substitute for insulin.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Do not use Wegovy&reg; in combination with other medicines that contain GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide or lixisenatide).</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar (hypoglycaemia)</p><p>Taking a sulfonylurea or an insulin with Wegovy&reg; might increase the risk of getting low blood sugar levels (hypoglycaemia). Please see section 4 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.</p><p>&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetic eye disease (retinopathy)</p><p>If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment. Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye problems while taking this medicine, talk to your doctor.</p><p>&nbsp;</p><p>Children and adolescents</p><p>This medicine is not recommended in children and adolescents under 18 years as the safety and effectiveness in this age group have not been established.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Other medicines and Wegovy&reg;&nbsp; &nbsp;</p><p>Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor, pharmacist or nurse if you are using medicines containing the following:&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anticoagulants). When you start treatment with e.g. wafarin or similar medicines, frequent blood testing to determine the ability of your blood to clot may be required.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped.</p><p>&nbsp;</p><p>Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Wegovy&reg; is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Wegovy&reg; mainly during the first 4 months of treatment (see section 4). If you feel dizzy be extra careful while driving or using machines. If you need any further information, talk to your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><em>People with type 2 diabetes </em></p><p>If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar</p><p>(hypoglycaemia) may occur which may reduce your ability to concentrate. Avoid driving or using machines if you get any signs of low blood sugar. See section 2, &lsquo;Warnings and precautions&rsquo; for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Wegovy&reg; contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodiumfree&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>How much to use</p><p>The recommended dose is 2.4 mg once weekly.</p><p>Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you first start using Wegovy&reg;, the starting dose is 0.25 mg once weekly.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once you reach the recommended dose of 2.4 mg, do not increase this dose further.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In case you are feeling very bothered by sickness (nausea) or by being sick (vomiting) talk with your doctor about delaying dose escalation or lowering to the previous dose until symptoms have improved.</p><p>&nbsp;</p><p>Usually, you will be told to follow the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Dose escalation</p></td><td><p>Weekly dose</p></td></tr><tr><td><p>Week 1&ndash;4</p></td><td><p>0.25 mg</p></td></tr><tr><td><p>Week 5&ndash;8</p></td><td><p>0.5 mg</p></td></tr><tr><td><p>Week 9&ndash;12</p></td><td><p>1 mg</p></td></tr><tr><td><p>Week 13&ndash;16</p></td><td><p>1.7 mg</p></td></tr><tr><td><p>From week 17&nbsp;</p></td><td><p>2.4 mg</p></td></tr></tbody></table><p>&nbsp;</p><p>Your doctor will assess your treatment on a regular basis.</p><p>&nbsp;</p><p>How Wegovy&reg; is given</p><p>Wegovy&reg; is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best places to give the injection are the front of your upper arm, upper legs or stomach.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use the pen for the first time, your doctor, pharmacist or nurse will show you how to use it.</p><p>&nbsp;</p><p>Detailed instructions on how to use the pen are on the other side of this leaflet.</p><p>&nbsp;</p><p>People with type 2 diabetes</p><p>Tell your doctor if you have type 2 diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.</p><p>&nbsp;</p><p>When to use Wegovy&reg;&nbsp; &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should use this medicine once a week and if possible, on the same day each week.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can give yourself the injection at any time of the day &ndash; regardless of meals.&nbsp;</p><p>&nbsp;</p><p>If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once a week dosing.</p><p>&nbsp;</p><p>If you use more Wegovy&reg; than you should</p><p>Talk to your doctor straight away. You may get side effects such as feeling sick (nausea), being sick (vomiting) or have diarrhoea, which may cause dehydration (loss of fluids).</p><p>&nbsp;</p><p>If you forget to use Wegovy&reg;&nbsp; &nbsp;</p><p>If you forgot to inject a dose and:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is 5 days or less since you should have used Wegovy&reg;, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is more than 5 days since you should have used Wegovy&reg;, skip the missed dose. Then inject your next dose as usual on your next scheduled day. Do not use a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop using Wegovy&reg;&nbsp;&nbsp;</p><p>Do not stop using this medicine without talking to your doctor.&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Serious side effects</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflamed pancreas (acute pancreatitis). Signs of inflamed pancreas may include severe and longlasting pain in your stomach, the pain may move to your back. You should see your doctor immediately if you experience such symptoms.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions (anaphylactic reactions, angioedema). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing difficulty, swelling, light-headedness, fast heartbeat, sweating and loss of consciousness or rapid swelling under the skin in areas such as the face, throat, arms and legs, which can be life threatening if throat swelling blocks the airway.</p><p>&nbsp;</p><p>Other side effects</p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or tired&nbsp;</p><p>&ndash; these are mainly seen during dose escalation and usually go away over time.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upset stomach or indigestion&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burping&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gas (flatulence)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed stomach (&lsquo;gastritis&rsquo;) &ndash; the signs include stomach-ache, feeling sick (nausea) or being sick (vomiting)&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reflux or heartburn &ndash; also called &lsquo;gastro-oesophageal reflux disease&rsquo;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallstones&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) in patients with type 2 diabetes.&nbsp;</p><p>&nbsp;</p><p>The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking.&nbsp;</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs.</p><p>Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy or lightheaded on standing or sitting up because of a drop in blood pressure <strong>&bull; </strong>fast heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of pancreatic enzymes (such as lipase and amylase) shown in blood tests.</p><p>&nbsp;</p><p>Reporting of side effects</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: <u>npc.drug@sfda.gov.sa</u></p></td></tr><tr><td><p>Website: <u>https://ade.sfda.gov.sa</u></p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p><strong>&nbsp;</strong></p><p>Before opening</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep away from the cooling element. Protect from light.</p><p>&nbsp;</p><p>During use</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can keep the pen for 6 weeks when stored at a temperature below 30&deg;C or in a refrigerator (2&deg;C &ndash; 8&deg;C) away from the cooling element. Do not freeze Wegovy&reg; and do not use it if it has been frozen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you are not using the pen, keep the pen cap on in order to protect from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the solution is not clear and colourless.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Wegovy&reg; contains&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is semaglutide.&nbsp;</p><p><u>Wegovy&reg; 0.25 mg solution for injection</u></p><p>Each pre-filled pen contains 1 mg semaglutide in 1.5 mL.</p><p>&nbsp;</p><p><u>Wegovy&reg; 0.5 mg solution for injection</u></p><p>Each pre-filled pen contains 2 mg semaglutide in 1.5 mL.</p><p>&nbsp;</p><p><u>Wegovy&reg; 1 mg solution for injection</u></p><p>Each pre-filled pen contains 4 mg semaglutide in 3 mL.</p><p>&nbsp;</p><p><u>Wegovy&reg; 1.7 mg solution for injection</u>&nbsp;</p><p>Each pre-filled pen contains 6.8 mg semaglutide in 3 mL.</p><p>&nbsp;</p><p><u>Wegovy&reg; 2.4 mg solution for injection</u>&nbsp;</p><p>Each pre-filled pen contains 9.6 mg of semaglutide in 3 mL.</p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid/sodium hydroxide (for pH adjustment), water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Wegovy® looks like and contents of the pack 
Wegovy® is a clear and colourless solution for injection in a pre-filled disposable pen.  
 
Each pen contains 4 doses. 
 
Wegovy® 0.25, 0.5, 1 and 1.7 mg solution for injection is available in the following pack size:  1 pre-filled pen and 4 disposable NovoFine Plus needles. 
 
Wegovy® 2.4 mg solution for injection is available in the following pack sizes:  1 pre-filled pen and 4 disposable NovoFine Plus needles. 
3 pre-filled pens and 12 disposable NovoFine Plus needles Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd</p><p>Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan/2022 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;ما دواء ويجوفيTM</p><p><br />ويجوفيTM هو دواء لفقدان الوزن والحفاظ عليه يحتوي على المادة الفعالة سيماجلوتايد. وهو يشبه هرموناً طبيعياً&nbsp; يسمى&nbsp; يبْتيد - 1 الشبيه بجلوكاجون GLP-1&nbsp;&nbsp;<br />يُفرز من الأمعاء بعد تناول الطعام. يعمل على المستقبلات الموجودة في الدماغ والتي تتحكم في شهيتك، مما تسبب لك الشعور بالشبع وتقليل الجوع وتقليل الرغبة في تناول الطعام. سيساعدك ذلك على تقلیل الحاجة إلى تناول الطعام وبالتالي إنقاص وزن الجسم.</p><p><br />ما دواعي استعمال ويجوفيTM<br />يُستخدم ويجوفيTM مع النظام الغذائي والنشاط البدني لفقدان الوزن وللمساعدة في إبقاء الوزن تحت السيطرة. ويُستخدم لدى البالغين،<br />الذين&nbsp;يبلغ</p><ul><li>مؤشر كتلة الجسم لديهم 30 كجم/م<sup>2&nbsp;</sup>أو أكثر (السمنة) أو</li><li>مؤشر كتلة الجسم لا یقل عن 27 كجم/م<sup>2&nbsp;</sup>ولكن أقل من 30 كجم/م &sup2;&nbsp;(وزن زائد) و&nbsp;يعانون من مشكلات صحية مرتبطة بالوزن</li></ul><p>(مثل السكري وارتفاع ضغط الدم ومستويات الدهون غير الطبيعية في الدم أو مشاكل التنفس أثناء النوم، والتي تسمى &quot;انقطاع&nbsp;النفس الانسدادي النومي&quot; أو تاريخ من الإصابة بنوبة قلبية أو سكتة دماغية أو مشكلات الأوعیة الدموية).</p><p>مؤشر كتلة الجسم&nbsp;(BMI)هو مقياس لوزن الجسم بالنسبة إلى طوله.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم ويجوفيTM</p><ul><li>&nbsp;إذا كنت تعاني من الحساسية من مادة سيماجلوتايد أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6)</li></ul><p><br />تحذيرات واحتياطات</p><p><br />&nbsp;استشر طبيبك أو الصيدلي أو اختصاصي التمريض قبل استعمال&nbsp;ويجوفيTM<br />لايوصى باستخدام &nbsp;ويجوفيTM إذا كنت:&nbsp;&nbsp;<br />&bull; تستخدم منتجات أخرى لفقدان الوزن،<br />&bull; مصاب بداء السكري من النوع الأول<br />&bull; تعاني من قصور شديد في وظائف الكلى<br />&bull; تعاني من قصور شديد في وظائف الكبد<br />&bull; تعاني من قصور حاد في القلب<br />&bull; تعاني من مرض العين المرتبط بالسكري (اعتلال الشبكية)<br />&nbsp; لا توجد سوى تجارب قليلة حول استعمال&nbsp;ويجوفيTMعلى المرضى:<br />&bull; الذين يبلغون من العمر 75 عاماً فأكثر،<br />&bull; الذين يعانون من مشكلات في الكبد،<br />&bull; الذين يعانون من مشكلة شديدة في المعدة أو الأمعاء تؤدي إلى إفراغ المعدة المتأخر (يُطلق عليه خزل المعدة)، أو إذا كانوا مصابين بمرض التهاب الأمعاء.<br />يُرجى استشارة طبيبك إذا كان أي مما سبق ينطبق عليك.</p><ul><li>الجفاف</li><li>الآثار على الجهاز الهضمي</li></ul><p><br />قد تشعر أثناء العلاج بدواء ويجوفيTM&nbsp;بتعب (غثيان) أو توعك (قيء) أو قد تُصاب بإسهال. يمكن أن تسبب هذه الآثار الجانية&nbsp;<br />الجفاف (فقدان السوائل). ومن ثمّ فإنه من المهم أن تشرب كمية كافية من السوائل لمنع الجفاف. وتزداد أهمية ذلك إذا كنت تعاني<br />من مشاكل في الكلى. استشر الطبيب إذا كانت لديك أية استفسارات.</p><p>&nbsp;</p><ul><li>التهاب البنكرياس&nbsp;</li><li>إذا كنت تعاني من ألم شديد ومستمر في منطقة المعدة (انظر القسم 4) - يُرجى استشارة الطبيب على الفور لأن ذلك قد يكون</li></ul><p>علامة على التهاب البنكرياس (التهاب البنكرياس الحاد).مرضى السكري من النوع الثاني<br />لا يمكن استخدام ويجوفيTM&nbsp;كبديل للإنسولين. لا تستخدم ويجوفيTM مع أدویة أخرى محتوية على ناهضات مستقبلات جي إل بي- TM .&nbsp;<br />1 (مثل ليراجلوتايد، أو دولاجلوتايد، أو إكسيناتايد أو ليكيسيناتايد).</p><p>&nbsp;</p><p>انخفاض مستوى السكر في الدم&nbsp;</p><p>قد يزيد تناول دواء السلفونيل يوريا أو الإنسولين مع ويجوفيTM من خطر الإصابة بانخفاض مستويات السكر في الدم. يُرجى الاطلاع على القسم 4 للتعرف على العلامات التحذيرية لانخفاض مستويات السكر في الدم. قد يطلب منك الطبيب اختبار مستويات السكر في الدم. إذ سيساعد ذلك طبيبك على تحديد ما إذا كان يجب تغيير جرعة السلفونيل&nbsp; يوريا أو الإنسولين لتقليل خطر انخفاض السكر في الدم أم لا.</p><p>&nbsp;</p><ul><li>مرض العين المرتبط بالسكري (اعتلال الشبكية)&nbsp;</li></ul><p>إذا كنت تعاني من مرض العين المرتبط بالسكري وتستخدم الإنسولين، فقد يؤدي هذا الدواء إلى تدهور الرؤية لديك، وقد يتطلب ذلك علاجًا. قد تؤدي التحسينات السريعة في التحكم في مستوى السكر في الدم إلى تفاقم مرض العين السكري بشكل مؤقت. فإذا كنت مصابًا بمرض العين المرتبط بالسكري وكنت تعاني من مشاكل في العين أثناء تناول هذا الدواء، فيُرجى استشارة الطبيب.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p>لا يُنصح بإعطاء هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا لعدم ثبوت سلامته وفعاليته في هذه الفئة العمرية.</p><p><br />&nbsp;الأدوية الأخرى ودواء ويجوفيTM</p><p><br />أخبِر طبيبك أو اختصاصي التمريض أو الصيدلي بما إذا كنت تستخدم أي أدوية أخرى، أو تناولتها مؤخرًا، أو قد تتناولها.<br />وعلى وجه الخصوص، أخبر طبيبك أو الصيدلي أو اختصاصي التمريض إذا كنت تستخدم أدوية تحتوي على ما يلي:<br />&bull; وارفارين أو أدوية مماثلة أخرى تُؤخذ عن طريق&nbsp;الفم لتقليل تخثر الدم (مضادات التخثر الفموية). عندما تبدأ العلاج مع، على سبيل المثال، الوارفارين أو الأدوية المماثلة، فقد تكون هناك حاجة لإجراء فحوصات دم متكررة لتحديد مستوى قدرة دمك على التخثر.</p><p><br />الحمل والرضاعة الطبيعية<br />يجب عدم استخدام هذا الدواء أثناء الحمل، لأنه من غير المعروف ما إذا كان قد يؤثر على جنينك أم لا. ومن ثمّ فإنه، يُوصى باستخدام<br />موانع الحمل أثناء تناول هذا الدواء. إذا كنتِ ترغبين في الحمل، فيجب عليكِ التوقف عن استخدام هذا الدواء قبل شهرين على الأقل. إذا<br />أصبحتِ أو كنتِ حاملًا، أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل عند استخدام هذا الدواء، فتحدثي إلى طبيبكِ على الفور، حيث<br />سيتعين إيقاف علاجكِ.<br />لا تستخدمي هذا الدواء إذا كنتِ ترضعين طفلك رضاعة طبيعية ، لأنه من غير معروف ما إذا كان ينتقل إلى حليب الثدي أم لا.</p><p><br />قيادة المركبات واستخدام الآلات<br />من غير المحتمل أن يؤثر ويجوفيTM&nbsp;على القيادة واستخدام الآلات. قد يشعر بعض المرضى بالدوار عند تناول&nbsp; ويجوفيTMبشكل أساسي&nbsp; خلال أول 4 أشهر من العلاج (انظر القسم 4). إذا شعرت بالدوار، فتوخِ الحذر الشديد أثناء القيادة أو استخدام الآلات. إذا كانت لديك أي استفسارات أخرى استشر طبيبك أو الصيدلي أو اختصاصي التمريض.</p><p><br />مرضى السكري من النوع الثاني</p><p><br />إذا كنت تستخدم هذا الدواء مع السلفونيل یوريا أو الإنسولين، قد ينخفض مستوى السكر في دمك، مما قد يقلل من قدرتك على التركيز.<br />ومن ثمّ فإنه&nbsp;يجب تجنب قيادة المركبات أو استخدام الآلات إذا ظهرت عليك أي علامات لانخفاض مستوى السكر في الدم. راجع القسم 2، &quot;تحذيرات واحتياطات&quot; للحصول على معلومات حول زيادة خطر انخفاض سكر الدم والقسم 4 للحصول على العلامات التحذيرية<br />لانخفاض سكر الدم. وتحدّث إلى الطبيب للحصول على مزيد من المعلومات.<br />يحتوي ويجوفيTM على الصوديوم&nbsp;<br />يحتوي هذا الدواء على أقل من 1 مللي مول صوديوم ( 23 ملجم) لكل جرعة، وهذا يعني أنه تقريبًا &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب استعمال هذا الدواء دائمًا كما أخبرك الطبيب تمامًا. ويجب استشارة الطبيب أو الصيدلاني أو اختصاصي التمريض في حالة عدم التأكد من طريقة استخدامه على الوجه الصحيح.</p><p><br />جرعة الاستخدام<br />الجرعة الموصى بها هي 2.4 ملجم مرة واحدة أسبوعيًا.</p><p>يبدأ العلاج بأخذ جرعة منخفضة، ثم تزداد الجرعة تدريجيًا على مدار 16 أسبوعًا من العلاج.</p><ul><li>عند استخدام ويجوفيTM لأول مرة، تكون جرعة البداية هي 0.25 ملجم مرة واحدة أسبوعيًا.&nbsp;</li><li>سيطلب منك طبيبك زيادة جرعتك تدريجيًا كل 4 أسابيع حتى تصل إلى الجرعة الموصى بها البالغة 2.4 ملجم مرة واحدة أسبوعيًا.</li><li>بمجرد وصولك إلى الجرعة الموصى بها البالغة 2.4 ملجم، لا تزيد هذه الجرعة أكثر من ذلك.&nbsp;</li><li>في حالة شعورك بالضيق الشديد بسبب التعب (الغثيان) أو بالتوعك (القيء)، فتحدث مع طبيبك حول تأخير زيادة الجرعة أو خفضها إلى الجرعة السابقة حتى تتحسن الأعراض.</li></ul><p>وعادةً ما يطلب منك الطبيب إتباع الجدول التالي.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>زيادة الجرعة</td><td>جرعة أسبوعیة</td></tr><tr><td>&nbsp;الأسبوع 1-4</td><td>0.25 ملجم</td></tr><tr><td>الأسبوع 5-8</td><td>0.5 ملجم</td></tr><tr><td>الأسبوع 9-12</td><td>1 ملجم</td></tr><tr><td>الأسبوع 13-16</td><td>1.7 ملجم</td></tr><tr><td>بدايةً من الأسبوع 17</td><td>2.4 ملجم</td></tr></tbody></table><p><br />سيقيم الطبيب مدى فعالية العلاج لحالتك بصفة منتظمة.</p><p><br />&nbsp;كيفية إعطاء ويجوفيTM</p><p><br />&nbsp;تؤخذ جرعة ويجوفيTM كحقنة تحت الجلد. لا تحقن في الأوردة ولا في العضلات.</p><ul><li>أفضل الأماكن لإعطاء الحقنة هي الجزء الأمامي من أعلى الذراعين أو الفخذين أو منطقة البطن.</li><li>قبل استعمال القلم لأول مرة، اطلب من طبيبك أو الصيدلي أو اختصاصي التمريض شرح كيفية استعماله.&nbsp;</li></ul><p>التعليمات المفصلة حول طريقة استخدام القلم موضحة في الجانب الآخر من هذه النشرة.</p><p><br />مرضى السكري من النوع الثاني</p><p><br />يرجى إبلاغ الطبيب إذا كنت تعاني من داء السكري من النوع الثاني. فقد يعدل طبيبك الجرعة التي تأخذها من أدوية السكري لوقايتك من<br />انخفاض السكر في الدم.</p><p><br />&nbsp;متى يجب استخدام ويجوفيTM</p><ul><li>يجب عليك استخدام هذا الدواء مرة واحدة أسبوعيًا، وإن أمكن، في نفس اليوم من كل أسبوع.</li><li>يمكنك إعطاء نفسك الحقنة في أي وقت من اليوم - دون التقيد بالوجبات.</li></ul><p>لمساعدتك على تذكّر حقن هذا الدواء مرة واحدة في الأسبوع فقط، يوصى بتدوين يوم الأسبوع المحدد (على سبيل المثال الأربعاء) على<br />الكرتون وكتابة التاريخ على الكرتون في كل مرة تقوم بالحقن.<br />إذا لزم الأمر، يمكنك تغيير يوم الحقن الأسبوعي من يذا الدواء طالما مر 3 أيام على الأقل منذ آخر حقنة لك. بعد تحديد يوم جديد للجرعة، استمر بجرعة واحدة في الأسبوع.</p><p>في حالة استعمال جرعة ويجوفيTM أكثر مما ينبغي</p><p><br />تحدث إلى طبيبك على الفور. إذ قد تظهر عليك آثار جانبية مثل الشعور بالتعب (الغثيان)، أو الشعور بالمرض (القيء) أو الإسهال، مما<br />قد يسبب الجفاف (فقدان السوائل).</p><p><br />إذا نسيت استخدام ويجوفيTM</p><p><br />إذا نسيت حقن إحدى الجرعات و:</p><ul><li>مضت 5 أيام أو أقل على الموعد المحدد لاستخدام ويجوفيTM،&nbsp; فاستخدمه بمجرد أن تتذكر. ثم احقن جرعتك التالية كالمعتاد في&nbsp;اليوم المقرر.</li><li>مضت أكثر من 5 أيام على الموعد المحدد لاستخدام ويجوفيTM،&nbsp; فتخطى الجرعة الفائتة. ثم احقن جرعتك التالية كالمعتاد في&nbsp;اليوم المقرر التالي.</li></ul><p>لا تتناول جرعة مضاعفة لتعويض الجرعة التي فاتتك.</p><p><br />&nbsp;إذا توقفت عن استخدام ويجوفيTM<br />لا تتوقف عن استخدام هذا الدواء دون استشارة الطبيب.<br />إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، ينبغي استشارة الطبيب أو الصيدلاني أو اختصاصي التمريض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية وإن كانت لا تحدث عند جميع الأشخاص الذين يستخدمونه.</p><p><br />الآثار الجانبية الخطيرة<br />شائعة (قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص)</p><ul><li>مضاعفات مرض العين المرتبط بالسكري (اعتلال الشبكية السكري). إذا كنت تعاني من داء السكري، فيجب أن تخبر الطبيب إذا كنت تعاني من مشكلات في العين، مثل تغيرات في الرؤية، أثناء العلاج بهذا الدواء.</li></ul><p>غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص)</p><p>&nbsp;</p><ul><li>التهاب البنكرياس (التهاب البنكرياس الحاد). قد تشمل علامات التهاب البنكرياس ألمًا شديدًا وممتدًا في معدتك، قد ينتقل الألم إلى ظهرك. يجب عليك زيارة الطبيب على الفور إذا ظهرت عليك مثل هذه الأعراض.</li></ul><p>نادرة (قد تصيب ما يصل إلى شخص واحد من بين 1000 شخص)</p><p>&nbsp;</p><ul><li>ردود فعل تحسسية شديدة (تفاعلات تأقية، وذمة وعائية). يجب الحصول على مساعدة طبية فورية وإبلاغ الطبيب على الفور إذا ظهرت عليك أعراض مثل صعوبة التنفس والتورم والدوخة وسرعة ضربات القلب والتعرق وفقدان الوعي أو التورم السريع</li></ul><p>تحت الجلد في مناطق مثل الوجه والحلق والذراعين والساقين والتي يمكن أن تكون مهددة للحياة إذا تسبب تورم الحلق في انسداد مجرى الهواء.</p><p><br />آثار جانبية أخرى<br />شائعة جدًا (قد تصيب أكثر من شخص واحد من كل 10 أشخاص)</p><ul><li dir="rtl">الصُداع&nbsp;</li><li dir="rtl">الشعور بالإعياء (الغثيان)</li><li dir="rtl">الإعياء (التقيؤ)&nbsp;</li><li dir="rtl">الإسهال</li><li dir="rtl">الإمساك</li><li dir="rtl">ألم المعدة</li><li dir="rtl">شعور بالضعف أو التعب&nbsp;</li></ul><p>- تظهر بشكل أساسي في أثناء زيادة الجرعة وعادةً ما تزول بمرور الوقت.</p><p><br />شائعة (قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص)</p><ul><li>الشعور بالدوار</li><li>اضطراب المعدة أو عسر الهضم&nbsp;</li><li>التجشؤ&nbsp;</li><li>غاز (انتفاخ البطن)</li><li>انتفاخ المعدة&nbsp;</li><li>التهاب المعدة - ومن علاماتھا آلام المعدة أو الشعور بالتعب (الغثيان) أو الشعور بالإعياء (القيء)&nbsp;</li><li>الارتجاع أو حرقة المعدة - وتسمى أيضًا &quot;مرض الارتجاع المعدي المريئي&quot;</li><li>حصوات مرارية&nbsp;</li><li>تساقط الشعر&nbsp;</li><li>ردود فعل في موضع الحقن&nbsp;</li><li>انخفاض السكر في الدم (هبوط سكر الدم) لدى المرضى المصابين بالسكري.</li></ul><p>قد تظهر العلامات التحذيرية لانخفاض مستوى السكر في الدم فجأة. وقد تشمل ھذه العلامات: العرق البارد أو البشرة الباهتة الباردة أو<br />الصداع أو سرعة ضربات القلب أو الشعور بالإعياء (الغثيان) أو الجوع الشديد أو تغيرات الرؤية أو الشعور بالنعاس أو الضعف أو الشعور بالتوتر أو القلق أو الارتباك أو صعوبة التركيز أو الارتجاف.</p><p>سيخبرك الطبيب بكيفية علاج انخفاض مستوى السكر في الدم وماذا تفعل عند ملاحظة هذه العلامات التحذيرية.<br />ومن الأرجح أن يحدث انخفاض السكر في الدم إذا كنت تأخذ أيضًا سالفونيل يوريا أو إنسولين. ومن ثمّ فإن الطبيب قديقلل الجرعة الموصوفة لك من هذه الأدوية قبل البدء في استخدام هذا الدواء.</p><p><br />غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص)</p><p>&nbsp;</p><ul><li>انخفاض ضغط الدم</li><li>الشعور بدوار أو دوخة عند الوقوف أو الجلوس بسبب انخفاض ضغط الدم</li><li>سرعة ضربات القلب&nbsp;</li><li>زيادة إنزيمات البنكرياس (مثل الليباز والأميليز) الموضحة في اختبارات الدم.&nbsp;</li></ul><p>الإبلاغ عن الآثار الجانبية</p><table border="1" cellspacing="1" cellpadding="1" dir="ltr"><tbody><tr><td>المركز الوطني للتيقظ والسلامة الدوائية<br />+ فاكس: 2057662-11-966<br />للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999<br />npc.drug@sfda.gov.sa : بريد الالكتروني<br />/https://ade.sfda.gov.sa : الموقع الالكتروني</td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p><br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق القلم و الكرتون بعد كلمة&nbsp;&quot;EXP&quot; يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المسجل على الكرتون.</p><p><br />قبل الفتح:<br />خزّن المنتج في الثلاجة ( 2 - 8 درجات مئوية). يُحفظ بعيدًا عن مصدر التبريد. يُحفظ بعيدًا عن الضوء.&nbsp;</p><p><br />أثناء الاستعمال:</p><ul><li>يمكنك حفظ القلم لمدة 6 أسابیع عند تخزينه في درجة حرارة أقل من 30 درجة مئوية أو في الثلاجة ( 2 إلى 8 درجات مئوية)&nbsp;بعيدًا عن مصدر التبريد.</li></ul><p>&nbsp;لا تجمِّد ويجوفيTM ولا تستخدمه إذا كان مجمدًا.</p><ul><li>عند عدم استخدام القلم، يُرجى تغطيته بالغطاء لحمايته من الضوء.&nbsp;</li></ul><p>تجنب استخدام هذا الدواء إذا لاحظت أن المحلول غير صافي وعديم اللون.<br />لا تتخلص من أية أدوية في مياه الصرف الصحي أو النفایات المنزلية. اسأل الصیدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حمية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي</strong> <strong>يحتوي عليه دواء ويجوفي</strong><sup>TM</sup></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي سيماجلوتايد.</p><p dir="RTL"><u>محلول ويجوفي</u><sup>TM</sup><u> </u><u>0.25</u><u> ملجم للحقن</u></p><p dir="RTL">يحتوي كل قلم معبأ مسبقاً على 1 ملجم سيماجلوتايد في 1.5 مل.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>محلول ويجوفي</u><sup>TM</sup><u> </u><u>0.5</u><u> ملجم للحقن</u></p><p dir="RTL">يحتوي كل قلم معبأ مسبقاً على 2 ملجم سيماجلوتايد في 1.5 مل.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>محلول ويجوفي</u><sup>TM</sup><u> </u><u>1</u><u> ملجم للحقن</u></p><p dir="RTL">يحتوي كل قلم معبأ مسبقاً على 4 ملجم سيماجلوتايد في 3 مل.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>محلول ويجوفي</u><sup>TM</sup><u> </u><u>1.7</u><u> ملجم للحقن </u></p><p dir="RTL">يحتوي كل قلم معبأ مسبقاً على 6.8 ملجم سيماجلوتايد في 3 مل.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>محلول ويجوفي</u><sup>TM</sup><u> </u><u>2.4</u><u> ملجم للحقن </u></p><p dir="RTL">يحتوي كل قلم معبأ مسبقاً على <em>9.6</em> ملجم من سيماجلوتايد في <em>3</em> مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ثنائي هيدرات فوسفات ثنائي الصوديوم، وبروبيلين جلايكول، وفينول، وحمض الهيدروكلوريك/ هيدروكسيد صوديوم (لتعديل درجة الحموضة)، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل ويجوفي</strong> <sup>TM</sup><strong>ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ويجوفي<sup>TM</sup> هو محلول صافٍ وعديم اللون للحقن في قلم معبأ مسبقًا للاستعمال مرة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل قلم على أربع جرعات.</p><p dir="RTL">&nbsp;<u>يتوفر محلول ويجوفي</u><sup>TM</sup><u> بجرعة </u><u>0.25</u><u>، و</u><u>0.5</u><u>، و</u><u>1</u><u> و</u><u>1.7</u><u> ملجم&nbsp; للحقن بأحجام العبوات التالية: </u></p><p dir="RTL">قلم واحد معبأ مسبقًا و4 إبر نوفوفاين<sup>TM</sup> بلس صالحة للاستعمال مرة واحدة فقط.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><u>يتوفر محلول ويجوفي </u><sup>TM</sup><u>بجرعة </u><u>2.4</u><u> مجم للحقن بأحجام العبوات التالية: </u></p><p dir="RTL">قلم واحد معبأ مسبقًا و4 إبر نوفوفاين<sup>TM</sup> بلس صالحة للاستعمال مرة واحدة فقط.</p><p dir="RTL">3 أقلام معبأة مسبقًا و12 إبرة نوفوفاين<sup>TM</sup> بلس صالحة للاستعمال مرة واحدة فقط</p><p dir="RTL">لا يمكن تسويق جميع أحجام العبوات.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Novo Nordisk A/S<br />Novo All&eacute;<br />Bagsv&aelig;rd DK-2880<br />الدنمارك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2022 م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Wegovy 0.25 mg solution for injection in pre-filled pen 
Wegovy 0.5 mg solution for injection in pre-filled pen 
Wegovy 1 mg solution for injection in pre-filled pen 
Wegovy 1.7 mg solution for injection in pre-filled pen 
Wegovy 2.4 mg solution for injection in pre-filled pen 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre-filled pen, single-use 
 
Wegovy 0.25 mg solution for injection 
Each single-use pre-filled pen contains 0.25 mg semaglutide* in 0.5 mL solution. One mL of solution contains 0.5 mg of semaglutide*. 
 
Wegovy 0.5 mg solution for injection 
Each single-use pre-filled pen contains 0.5 mg semaglutide* in 0.5 mL solution. One mL of solution contains 1 mg of semaglutide*. 
 
Wegovy 1 mg solution for injection 
Each single-use pre-filled pen contains 1 mg semaglutide* in 0.5 mL solution. One mL of solution contains 2 mg of semaglutide*. 
 
Wegovy 1.7 mg solution for injection  
Each single-use pre-filled pen contains 1.7 mg semaglutide* in 0.75 mL solution. One mL of solution contains 2.27 mg of semaglutide*. 
 
Wegovy 2.4 mg solution for injection  
Each single-use pre-filled pen contains 2.4 mg semaglutide* in 0.75 mL solution. One mL of solution contains 3.2 mg of semaglutide*. 
 
Pre-filled pen, FlexTouch 
 
Wegovy 0.25 mg solution for injection 
Each pre-filled pen contains 1.0 mg semaglutide* in 1.5 mL solution. One mL of solution contains 0.68 mg semaglutide*. One pre-filled pen contains 4 doses of 0.25 mg (FlexTouch). 
 
Wegovy 0.5 mg solution for injection 
Each pre-filled pen contains 2 mg semaglutide* in 1.5 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 0.5 mg (FlexTouch). 
 
Wegovy 1 mg solution for injection 
Each pre-filled pen contains 4 mg semaglutide* in 3 mL solution. One mL of solution contains 1.34 mg semaglutide*. One pre-filled pen contains 4 doses of 1 mg (FlexTouch). 
 
Wegovy 1.7 mg solution for injection  
Each pre-filled pen contains 6.8 mg semaglutide* in 3 mL solution. One mL of solution contains 2.27 mg semaglutide*. One pre-filled pen contains 4 doses of 1.7 mg (FlexTouch). 
 
Wegovy 2.4 mg solution for injection  
Each pre-filled pen contains 9.6 mg semaglutide* in 3 mL solution. One mL of solution contains 3.2 mg semaglutide*. One pre-filled pen contains 4 doses of 2.4 mg (FlexTouch). 
 
*human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology. 
 
For the full list of excipients, see section 6.1.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection) 
Clear and colourless isotonic solution; pH=7.4. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;30 kg/m<sup>2</sup> (obesity), or&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity</p><p>e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The maintenance dose of semaglutide 2.4 mg once-weekly is reached by starting with a dose of</p><p>0.25 mg. To reduce the likelihood of gastrointestinal symptoms, the dose should be escalated over a 16-week period to a maintenance dose of 2.4 mg once weekly (see Table 1). In case of significant gastrointestinal symptoms, consider delaying dose escalation or lowering to the previous dose until symptoms have improved.&nbsp;</p><p>&nbsp;</p><p>Table 1 Dose escalation schedule</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Dose escalation </strong></p></td><td><p><strong>Weekly dose </strong></p></td></tr><tr><td><p>Week 1&ndash;4</p></td><td><p>0.25 mg</p></td></tr><tr><td><p>Week 5&ndash;8</p></td><td><p>0.5 mg</p></td></tr><tr><td><p>Week 9&ndash;12</p></td><td><p>1 mg</p></td></tr><tr><td><p>Week 13&ndash;16</p></td><td><p>1.7 mg</p></td></tr><tr><td><p><strong>Maintenance dose&nbsp; </strong></p></td><td><p>2.4 mg</p></td></tr></tbody></table><p>Weekly doses higher than 2.4 mg are not recommended.</p><p>&nbsp;</p><p><em><u>Patients with type 2 diabetes</u> </em></p><p>When initiating semaglutide in patients with type 2 diabetes, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia, see section 4.4.&nbsp;</p><p>&nbsp;</p><p><em><u>Missed dose</u> </em></p><p>If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule. If more doses are missed, reducing the starting dose for re-initiation should be considered.</p><p>&nbsp;</p><p><em><u>Special populations</u> </em></p><p><em>Elderly (&ge;65 years old) </em></p><p>No dose adjustment is required based on age. Therapeutic experience in patients &ge;75 years of age is limited, and greater sensitivity of some older individuals cannot be excluded.</p><p>&nbsp;</p><p><em>Patients with renal impairment&nbsp; </em></p><p>No dose adjustment is required for patients with mild or moderate renal impairment. Experience with the use of semaglutide in patients with severe renal impairment is limited. Semaglutide is not recommended for use in patients with severe renal impairment (eGFR &lt;30 mL/min/1.73m<sup>2</sup>) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Patients with hepatic impairment&nbsp; </em></p><p>No dose adjustment is required for patients with mild or moderate hepatic impairment. Experience with the use of semaglutide in patients with severe hepatic impairment is limited. Semaglutide is not recommended for use in patients with severe hepatic impairment and should be used cautiously in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Paediatric population </em></p><p>The safety and efficacy of semaglutide in children and adolescents below 18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p>Method of administration</p><p>Subcutaneous use.</p><p>&nbsp;</p><p>Wegovy is administered once weekly at any time of the day, with or without meals.&nbsp;</p><p>&nbsp;</p><p>It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed. It should not be administered intravenously or intramuscularly.</p><p>&nbsp;</p><p>The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (&gt;72 hours). After selecting a new dosing day, once-weekly dosing should be continued.</p><p>&nbsp;</p><p>When administering Wegovy, the pen should be pressed firmly against the skin until the yellow bar has stopped moving. The injection takes about 5&ndash;10 seconds.&nbsp;</p><p>&nbsp;</p><p>Patients should be advised to read the instruction for use included in the package leaflet carefully before administering the medicinal product.</p><p>&nbsp;</p><p>For further information before administration see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>Dehydration</p><p>Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions that can cause dehydration, which in rare cases can lead to a deterioration of renal function.</p><p>Patients&thinsp;should&thinsp;be&thinsp;advised of the potential risk of dehydration&thinsp;in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.</p><p>&nbsp;</p><p>Acute pancreatitis</p><p>Acute pancreatitis has been observed with the use of GLP-1 receptor agonists (see section 4.8). Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, semaglutide should be discontinued; if confirmed, semaglutide should not be restarted.</p><p>Caution should be exercised in patients with a history of pancreatitis.</p><p>In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis.</p><p>&nbsp;</p><p>Patients with type 2 diabetes</p><p>Semaglutide should not be used as a substitute for insulin in patients with type 2 diabetes.</p><p>&nbsp;</p><p>Semaglutide should not be used in combination with other GLP-1 receptor agonist products. It has not been evaluated and an increased risk of adverse reactions related to overdose is considered likely.</p><p>&nbsp;</p><p>Hypoglycaemia in patients with type 2 diabetes</p><p>Insulin and sulfonylurea are known to cause hypoglycaemia. Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with a GLP-1 receptor agonist. The addition of Wegovy in patients treated with insulin has not been evaluated.&nbsp;</p><p><em>&nbsp;</em></p><p>Diabetic retinopathy in patients with type 2 diabetes</p><p>In patients with diabetic retinopathy treated with semaglutide, an increased risk of developing diabetic retinopathy complications has been observed (see section 4.8). Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded. Patients with diabetic retinopathy using semaglutide should be monitored closely and treated according to clinical guidelines. There is no experience with Wegovy in patients with type 2 diabetes with uncontrolled or potentially unstable diabetic retinopathy. In these patients, treatment with Wegovy is not recommended.</p><p>&nbsp;</p><p>Populations not studied</p><p>The safety and efficacy of Wegovy have not been investigated in patients:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treated with other products for weight management,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with type 1 diabetes,</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe renal impairment (see section 4.2),</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe hepatic impairment (see section 4.2),&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with congestive heart failure New York Heart Association (NYHA) class IV. Use in these patients is not recommended.</p><p>&nbsp;</p><p>There is limited experience with Wegovy in patients:</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aged 75 years or more (see section 4.2),</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with mild or moderate hepatic impairment (see section 4.2), &ndash; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with inflammatory bowel disease, &ndash; &nbsp;&nbsp; with diabetic gastroparesis.</p><p>Use with caution in these patients.</p><p>&nbsp;</p><p>Sodium content</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Semaglutide delays gastric emptying and could potentially influence the absorption of concomitantly administered oral medicinal products. No clinically relevant effect on the rate of gastric emptying was observed with semaglutide 2.4 mg, probably due to a tolerance effect. Semaglutide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption.</p><p>&nbsp;</p><p>Paracetamol</p><p>Semaglutide delays the rate of gastric emptying as assessed by paracetamol pharmacokinetics during a standardised meal test. Paracetamol AUC<sub>0-60min</sub> and C<sub>max</sub> were decreased by 27% and 23%, respectively, following concomitant use of semaglutide 1 mg. The total paracetamol exposure (AUC<sub>0-5h</sub>) was not affected. No clinically relevant effect on paracetamol was observed with semaglutide. No dose adjustment of paracetamol is necessary when administered with semaglutide.</p><p><em>&nbsp;</em></p><p>Oral contraceptives</p><p>Semaglutide is not anticipated to decrease the effectiveness of oral contraceptives. It did not change the overall exposure of ethinylestradiol and levonorgestrel to a clinically relevant degree, when an oral contraceptive combination medicinal product (0.03 mg ethinylestradiol/0.15 mg levonorgestrel) was co-administered with semaglutide. Exposure of ethinylestradiol was not affected; an increase of 20% was observed for levonorgestrel exposure at steady state. C<sub>max</sub> was not affected for any of the compounds.</p><p>&nbsp;</p><p>Atorvastatin</p><p>Semaglutide did not change the overall exposure of atorvastatin following a single dose administration of atorvastatin (40 mg). Atorvastatin C<sub>max</sub> was decreased by 38%. This was assessed not to be clinically relevant.</p><p>&nbsp;</p><p>Digoxin</p><p>Semaglutide did not change the overall exposure or C<sub>max</sub> of digoxin following a single dose of digoxin (0.5 mg).</p><p>&nbsp;</p><p>Metformin</p><p>Semaglutide did not change the overall exposure or C<sub>max </sub>of metformin following dosing of 500 mg twice daily over 3.5 days.</p><p>&nbsp;</p><p>Warfarin</p><p>Semaglutide did not change overall exposure or C<sub>max </sub>of R- and S-warfarin following a single dose of warfarin (25 mg), and the pharmacodynamic effects of warfarin as measured by the international normalised ratio were not affected in a clinically relevant manner. However, upon initiation of semaglutide treatment in patients on warfarin or other coumarin derivatives, frequent monitoring of international normalised ratio (INR) is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential</p><p>Women of childbearing potential are recommended to use contraception when treated with semaglutide (see section 4.5).</p><p>&nbsp;</p><p>Pregnancy</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data from the use of semaglutide in pregnant women. Therefore, semaglutide should not be used during pregnancy.</p><p>If a patient wishes to become pregnant, or pregnancy occurs, semaglutide should be discontinued. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long halflife (see section 5.2).</p><p><em>&nbsp;</em></p><p>Breast-feeding</p><p>In lactating rats, semaglutide was excreted in milk. A risk to a breast-fed child cannot be excluded. Semaglutide should not be used during breast-feeding.</p><p>&nbsp;</p><p>Fertility</p><p>The effect of semaglutide on fertility in humans is unknown. Semaglutide did not affect male fertility in rats. In female rats, an increase in oestrous length and a small reduction in number of ovulations were observed at doses associated with maternal body weight loss.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Semaglutide has no or negligible influence on the ability to drive or use machines. However, dizziness can be experienced mainly during the dose escalation period. Driving or use of machines should be done cautiously if dizziness occurs.</p><p>&nbsp;</p><p>Patients with type 2 diabetes</p><p>&nbsp;</p><p>If semaglutide is used in combination with a sulfonylurea or insulin, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile</p><p>&nbsp;</p><p>In four phase 3a trials, 2,650 patients were exposed to Wegovy. The duration of the trials were 68 weeks. The most frequently reported adverse reactions were gastrointestinal disorders including nausea, diarrhoea, constipation and vomiting.&nbsp;</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>Table 2 lists adverse reactions identified in phase 3a clinical trials. The frequencies are based on a pool of the phase 3a trials.</p><p>&nbsp;</p><p>Adverse reactions associated with Wegovy are listed by system organ class and frequency. Frequency categories are defined as: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>Table 2 Adverse reactions from controlled phase 3 trials</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><thead><tr><td><p><strong>MedDRA</strong></p><p><strong>system organ class</strong></p></td><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td></tr></thead><tbody><tr><td><p>Immune system disorders</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p></td><td><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hypoglycaemia in patients with type 2 diabetes<sup>a</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache<sup>b</sup></p></td><td style="vertical-align:top"><p>Dizziness<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diabetic retinopathy in patients with type 2 diabetes<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p><p>Orthostatic hypotension</p><p>Increased heart rate<sup>a,c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting<sup>a,b</sup></p><p>Diarrhoea<sup>a,b</sup></p><p>Constipation<sup>a,b</sup></p><p>Nausea<sup>a,b</sup></p><p>Abdominal pain<sup>b,c</sup></p></td><td style="vertical-align:top"><p>Gastritis<sup>b,c</sup></p><p>Gastrooesophageal reflux disease<sup>b</sup></p><p>Dyspepsia<sup>b</sup></p><p>Eructation<sup>b</sup></p><p>Flatulence<sup>b</sup></p><p>Abdominal distension<sup>b</sup></p></td><td style="vertical-align:top"><p>Acute pancreatitis<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cholelithiasis<sup>a</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hair loss<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue<sup>b,c</sup></p></td><td style="vertical-align:top"><p>Injection site reactions<sup>c</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased amylase<sup>c</sup></p><p>Increased lipase<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a) </sup>see description of selected adverse reactions below</p><p><sup>b) </sup>mainly seen in the dose-escalation period</p><p><sup>c)</sup> Grouped preferred terms</p></td></tr><tr><td><p>&nbsp;</p></td></tr></tbody></table><p>Description of selected adverse reactions</p><p><em>&nbsp;</em></p><p><em><u>Gastrointestinal adverse reactions</u> </em></p><p>Over the 68 weeks trial period, nausea occurred in 43.9% of patients when treated with semaglutide (16.1% for placebo), diarrhoea in 29.7% (15.9% for placebo) and vomiting in 24.5% (6.3% for placebo). Most events were mild to moderate in severity and of short duration. Constipation occurred in 24.2% of patients treated with semaglutide (11.1% for placebo) and was mild to moderate in severity and of longer duration. In patients treated with semaglutide, median duration of nausea was 8 days, vomiting 2 days, diarrhoea 3 days, and constipation 47 days.</p><p>&nbsp;</p><p>Patients with moderate renal impairment (eGFR &ge;30 mL/min/1.73m<sup>2</sup>) may experience more gastrointestinal effects when treated with semaglutide.</p><p>&nbsp;</p><p>The gastrointestinal events led to permanent treatment discontinuation in 4.3% of patients.</p><p>&nbsp;</p><p><em><u>Acute pancreatitis</u> </em></p><p>The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical trials was 0.2% for semaglutide and &lt;0.1% for placebo, respectively.&nbsp;</p><p>&nbsp;</p><p><em><u>Acute gallstone disease/Cholelithiasis</u> </em></p><p>Cholelithiasis was reported in 1.6% and led to cholecystitis in 0.6% of patients treated with semaglutide. Cholelithiasis and cholecystitis was reported in 1.1% and 0.3%, respectively, of patients treated with placebo.</p><p>&nbsp;</p><p><em><u>Hair loss</u> </em></p><p>Hair loss was reported in 2.5% of patients treated with semaglutide and in 1.0% of patients treated with placebo. The events were mainly of mild severity and most patients recovered while on continued treatment. Hair loss was reported more frequently in patients with a greater weight loss (&ge;20%).</p><p>&nbsp;</p><p><em><u>Increased heart rate</u>&nbsp; </em></p><p>In the phase 3a trials, a mean increase of 3 beats per minute (bpm) from a baseline mean of 72 bpm was observed in patients treated with semaglutide. The proportions of subjects with an increase in pulse from baseline &ge;10 bpm at any timepoint during the on-treatment period were 67.0% in the semaglutide group vs. 50.1% in the placebo group.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u> </em></p><p>Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. The proportion of patients testing positive for anti-semaglutide antibodies at any time post-baseline was low (2.9%) and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous GLP-1 neutralising effect at end-of-trial. During treatment, high semaglutide concentrations might have lowered the sensitivity of the assays, hence the risk of false negatives cannot be excluded. However, in subjects testing positive for antibodies during and after treatment, the presence of antibodies was transient and with no apparent impact on efficacy and safety.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia in patients with type 2 diabetes</u> </em></p><p>In STEP 2, clinically significant hypoglycaemia was observed in 6.2% (0.1 events/patient year) of subjects treated with semaglutide compared with 2.5% (0.03 events/patient year) of subjects treated with placebo. Hypoglycaemia with semaglutide was seen both with and without concomitant use of sulfonylurea. One episode (0.2% of subjects, 0.002 events/patient year) was reported as severe in a subject not concomitantly treated with a sulfonylurea. The risk of hypoglycaemia was increased when semaglutide was used with a sulfonylurea.&nbsp;</p><p>&nbsp;</p><p><em><u>Diabetic retinopathy in patients with type 2 diabetes</u> </em></p><p>A 2-year clinical trial investigated semaglutide 0.5 mg and 1 mg vs. placebo in 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. In this trial, adjudicated events of diabetic retinopathy complications occurred in more patients treated with semaglutide (3.0%) compared to placebo (1.8%). This was observed in insulintreated patients with known diabetic retinopathy. The treatment difference appeared early and persisted throughout the trial. In STEP 2, retinal disorders were reported by 6.9% of patients treated with Wegovy, 6.2% of patients treated with semaglutide 1 mg, and 4.2% of patients treated with placebo. The majority of events were reported as diabetic retinopathy (4.0%, 2.7%, and 2.7%, respectively) and non-proliferative retinopathy (0.7%, 0%, and 0%, respectively).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Please report adverse drug events to:</u>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: <u>npc.drug@sfda.gov.sa</u></p></td></tr><tr><td><p>Website: <u>https://ade.sfda.gov.sa</u></p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with semaglutide may be associated with gastrointestinal disorders which could lead to dehydration. In the event of overdose the patient should be observed for clinical signs and appropriate supportive treatment initiated.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ06</p><p>&nbsp;</p><p>Mechanism of action</p><p>Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.</p><p>&nbsp;</p><p>GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.&nbsp;</p><p>&nbsp;</p><p>Animal studies show that semaglutide works in the brain through the GLP-1 receptor. Semaglutide has direct effects on areas in the brain involved in homeostatic regulation of food intake in the hypothalamus and the brainstem. Semaglutide may affect the hedonic reward system through direct and indirect effects in brain areas including the septum, thalamus and amygdala.</p><p>&nbsp;</p><p>Clinical studies show that semaglutide reduces energy intake, increases feelings of satiety, fullness and control of eating, reduces feelings of hunger, and frequency and intensity of cravings. In addition, semaglutide reduces the preference for high fat foods.</p><p>&nbsp;</p><p>Semaglutide orchestrates the homeostatic and hedonic contributions with executive function to regulate caloric intake, appetite, reward and food choice.</p><p>&nbsp;</p><p>In addition, in clinical studies semaglutide have shown to reduce blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. During hypoglycaemia, semaglutide diminishes insulin secretion and does not impair glucagon secretion.&nbsp;</p><p>&nbsp;</p><p>GLP-1 receptors are also expressed in the heart, vasculature, immune system and kidneys. Semaglutide has a beneficial effect on plasma lipids, lowered systolic blood pressure and reduced inflammation in clinical studies. Furthermore, animal studies have shown that semaglutide attenuated the development of atherosclerosis and had an anti-inflammatory action in the cardiovascular system.</p><p>&nbsp;</p><p>Pharmacodynamic effects</p><p>&nbsp;</p><p><em><u>Appetite, energy intake and food choice</u></em></p><p>Semaglutide reduces appetite by increasing feelings of fullness and satiety, while lowering hunger and prospective food consumption. After 20 weeks of dosing, energy intake during an ad libitum meal was 35% lower with semaglutide compared to placebo. This was supported by improved control of eating, less food cravings and a relative lower preference for high fat food.</p><p>&nbsp;</p><p><em><u>Fasting and postprandial lipids</u>&nbsp; </em></p><p>Semaglutide 1 mg compared to placebo lowered fasting triglyceride and very low density lipoproteins (VLDL) concentrations by 12% and 21%, respectively. The postprandial triglyceride and VLDL response to a high fat meal was reduced with &gt;40%.</p><p>&nbsp;</p><p>Clinical efficacy and safety</p><p>The efficacy and safety of semaglutide for weight management in combination with a reduced calorie intake and increased physical activity were evaluated in four double-blinded randomised placebocontrolled phase 3a trials (STEP 1-4). A total of 4,684 patients (2,652 randomised to treatment with semaglutide) were included in the trials.&nbsp;</p><p>&nbsp;</p><p>Treatment with semaglutide demonstrated superior, clinically meaningful, and sustained weight loss compared with placebo in patients with obesity (BMI &ge;30 kg/m<sup>2</sup>), or overweight (BMI &ge;27 kg/m<sup>2</sup> to</p><p>&lt;30 kg/m<sup>2</sup>) and at least one weight-related comorbidity. Furthermore, across the trials, a higher proportion of patients achieved &ge;5%, &ge;10%, &ge;15% and &ge;20% weight loss with semaglutide compared with placebo. The reduction in body weight occurred irrespective of the presence of gastrointestinal symptoms such as nausea, vomiting or diarrhoea.</p><p>&nbsp;</p><p>Treatment with semaglutide also showed statistically significant improvements in waist circumference, systolic blood pressure and physical functioning compared to placebo.&nbsp;</p><p>&nbsp;</p><p>Efficacy was demonstrated regardless of age, sex, race, ethnicity, baseline body weight, BMI, presence of type 2 diabetes and level of renal function. Variations in efficacy existed within all subgroups. Relatively greater weight loss was observed in women and in patients without type 2 diabetes as well as in patients with a lower versus higher baseline body weight.</p><p>&nbsp;</p><p><em><u>STEP 1: Weight management</u> </em></p><p>In a 68-week double-blind trial, 1,961 patients with obesity (BMI &ge;30 kg/m<sup>2</sup>), or with overweight (BMI &ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) and at least one weight-related comorbidity were randomised to semaglutide or placebo. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.</p><p>&nbsp;</p><p>Weight loss occurred early and continued throughout the trial. At end of treatment (week 68), the weight loss was superior and clinically meaningful compared with placebo (see Table 3 and Figure 1). Furthermore, a higher proportion of patients achieved &ge;5%, &ge;10%, &ge;15% and &ge;20% weight loss with semaglutide compared with placebo (see Table 3). Among patients with prediabetes at baseline, a higher proportion of patients had a normo-glycaemic status at end of treatment with semaglutide compared to placebo (84.1% vs. 47.8%).</p><p>&nbsp;</p><p>Table 3 STEP 1: Results at week 68</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Wegovy </strong></p></td><td><p><strong>Placebo </strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>1,306</p></td><td><p>655</p></td></tr><tr><td><p><strong>Body weight</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline (kg)<strong> </strong></p></td><td><p>105.4</p></td><td><p>105.2</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (%) from baseline<sup>1,2</sup><strong> </strong></p></td><td><p>-14.9</p></td><td><p>-2.4</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (%) from placebo<sup>1</sup> [95% CI] <strong>&nbsp;</strong></p></td><td><p>-12.4 [-13.4; -11.5]*</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (kg) from baseline</p></td><td><p>-15.3</p></td><td><p>-2.6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (kg) from placebo<sup>1</sup> [95% CI]&nbsp;</p></td><td><p>-12.7 [-13.7; -11.7]</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;5%<sup>3</sup>&nbsp;</p></td><td><p>83.5*<sup> </sup>&nbsp;</p></td><td><p>31.1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;10%<sup>3</sup>&nbsp;</p></td><td><p>66.1*<sup> </sup>&nbsp;</p></td><td><p>12.0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;15%<sup>3</sup>&nbsp;</p></td><td><p>47.9*<sup> </sup>&nbsp;</p></td><td><p>4.8</p></td></tr><tr><td><p><strong>Waist circumference (cm)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline</p></td><td><p>114.6</p></td><td><p>114.8</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup></p></td><td><p>-13.5</p></td><td><p>-4.1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>-9.4 [-10.3; -8.5]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Systolic blood pressure<sub> </sub>(mmHg) </strong>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<strong> </strong></p></td><td><p>126</p></td><td><p>127</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup><strong> </strong></p></td><td><p>-6.2</p></td><td><p>-1.1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1</sup> [95% CI]<strong> </strong></p></td><td><p>-5.1 [-6.3; -3.9]*</p></td><td><p>-</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>* </sup>p&lt;0.0001 (unadjusted 2-sided) for superiority.</p><p><sup>1 </sup>Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.</p><p><sup>2 </sup>During the trial, randomised treatment was permanently discontinued by 17.1% and 22.4% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed Model for Repeated Measures including all observations until first discontinuation were -16.9% and -2.4% for semaglutide 2.4 mg and placebo respectively.</p><p><sup>3 </sup>Estimated from binary regression model based on same imputation procedure as in primary analysis.&nbsp;</p><p><img alt="" width="601" height="299" src="data:image/png;base64,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" /></p><p>Figure 1 STEP 1: Mean change in body weight (%) from baseline to week 68</p><p>&nbsp;</p><p><em><u>STEP 2: Weight management in patients with type 2 diabetes</u></em></p><p>In a 68-week, double-blind trial, 1,210 patients with overweight or obesity (BMI &ge;27 kg/m<sup>2</sup>) and type 2 diabetes were randomised to either semaglutide 2.4 mg, semaglutide 1 mg once-weekly or placebo. Patients included in the trial had insufficiently controlled diabetes (HbA<sub>1c</sub> 7&ndash;10%) and were treated with either: diet and exercise alone or 1&ndash;3 oral antidiabetic drugs. All patients were on a reduced-calorie diet and increased physical activity throughout the trial.</p><p>&nbsp;</p><p>Treatment with semaglutide for 68 weeks resulted in superior and clinically meaningful reduction in body weight and in HbA<sub>1c</sub> compared to placebo (see Table 4 and Figure 2).</p><p>&nbsp;</p><p>Table 4 STEP 2: Results at week 68<em> </em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Wegovy </strong></p></td><td><p><strong>Placebo </strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>404</p></td><td><p>403</p></td></tr><tr><td><p><strong>Body weight </strong>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline (kg)<strong> </strong></p></td><td><p>99.9</p></td><td><p>100.5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (%) from baseline<sup>1,2</sup><strong> </strong></p></td><td><p>-9.6</p></td><td><p>-3.4</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (%) from placebo<sup>1</sup> [95% CI] <strong>&nbsp;</strong></p></td><td><p>-6.2 [-7.3;-5.2]*</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (kg) from baseline</p></td><td><p>-9.7</p></td><td><p>-3.5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (kg) from placebo<sup>1</sup> [95% CI]&nbsp;</p></td><td><p>-6.1 [-7.2;-5.0]</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;5%<sup>3</sup>&nbsp;</p></td><td><p>67.4*</p></td><td><p>30.2</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;10%<sup>3</sup>&nbsp;</p></td><td><p>44.5*</p></td><td><p>10.2</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;15%<sup>3</sup>&nbsp;</p></td><td><p>25.0*</p></td><td><p>4.3</p></td></tr><tr><td><p><strong>Waist circumference (cm)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline</p></td><td><p>114.5</p></td><td><p>115.5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup></p></td><td><p>-9.4</p></td><td><p>-4.5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1</sup> [95% CI]</p></td><td><p>-4.9 [-6.0; -3.8]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Systolic blood pressure<sub> </sub>(mmHg) </strong>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<strong> </strong></p></td><td><p>130</p></td><td><p>130</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup><strong> </strong></p></td><td><p>-3.9</p></td><td><p>-0.5</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1 </sup>[95% CI]<strong> </strong></p></td><td><p>-3.4 [-5.6; -1.3]**</p></td><td><p>-</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub> (mmol/mol (%))</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<strong> </strong></p></td><td><p>65.3 (8.1)</p></td><td><p>65.3 (8.1)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup></p></td><td><p>-17.5 (-1.6)</p></td><td><p>-4.1 (-0.4)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1</sup> [95% CI]<strong> </strong></p></td><td><p>-13.5 [-15.5; -11.4]</p><p>(-1.2 [-1.4; -1.1])*</p></td><td><p>-</p><p>-</p></td></tr></tbody></table><p>* p&lt;0.0001 (unadjusted 2-sided) for superiority; **p&lt;0.05 (unadjusted 2-sided) for superiority</p><p><sup>1&nbsp; </sup>Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.</p><p><sup>2&nbsp; </sup>During the trial, randomised treatment was permanently discontinued by 11.6% and 13.9% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed</p><p>Model for Repeated Measures including all observations until first discontinuation were -10.6% and -3.1% for semaglutide 2.4 mg and placebo respectively</p><p><sup>3&nbsp; </sup>Estimated from binary regression model based on same imputation procedure as in primary analysis.&nbsp;</p><p><img alt="" width="397" height="276" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts</p><p>Figure 2 STEP 2: Mean change in body weight (%) from baseline to week 68</p><p>&nbsp;</p><p><em><u>STEP 3: Weight management with intensive behavioural therapy</u></em></p><p>In a 68-week double-blind trial, 611 patients with obesity (BMI &ge;30 kg/m<sup>2</sup>), or with overweight (BMI</p><p>&ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) and at least one weight-related comorbidity were randomised to semaglutide or placebo. During the trial, all patients received intensive behavioural therapy (IBT) consisting of a very restrictive diet, increased physical activity and behavioural counselling.</p><p>&nbsp;</p><p>Treatment with semaglutide and IBT for 68 weeks resulted in superior and clinically meaningful reduction in body weight compared to placebo (see Table 5).</p><p>&nbsp;</p><p>Table 5 STEP 3: Results at week 68</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Wegovy </strong></p></td><td><p><strong>Placebo </strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>407</p></td><td><p>204</p></td></tr><tr><td><p><strong>Body weight</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline (kg)<strong> </strong></p></td><td><p>106.9</p></td><td><p>103.7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (%) from baseline<sup>1,2</sup><strong> </strong></p></td><td><p>-16.0</p></td><td><p>-5.7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (%) from placebo<sup>1</sup> [95% CI] <strong>&nbsp;</strong></p></td><td><p>-10.3 [-12.0;-8.6]*</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (kg) from baseline</p></td><td><p>-16.8</p></td><td><p>-6.2</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (kg) from placebo<sup>1</sup> [95% CI]&nbsp;</p></td><td><p>-10.6 [-12.5;-8.8]</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;5%<sup>3</sup></p></td><td><p>84.8*</p></td><td><p>47.8</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;10%<sup>3</sup></p></td><td><p>73.0*</p></td><td><p>27.1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Patients (%) achieving weight loss &ge;15%<sup>3</sup></p></td><td><p>53.5*</p></td><td><p>13.2</p></td></tr><tr><td><p><strong>Waist circumference (cm)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<strong> </strong></p></td><td><p>113.6</p></td><td><p>111.8</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup><strong> </strong></p></td><td><p>-14.6</p></td><td><p>-6.3</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1</sup> [95% CI]<strong> </strong></p></td><td><p>-8.3 [-10.1; -6.6]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Systolic blood pressure<sub> </sub>(mmHg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline</p></td><td><p>124</p></td><td><p>124</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup></p></td><td><p>-5.6</p></td><td><p>-1.6</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>1 </sup>[95% CI]</p></td><td><p>-3.9 [-6.4; -1.5]*</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* p&lt;0.005 (unadjusted 2-sided) for superiority</p><p><sup>1&nbsp; </sup>Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.&nbsp;</p><p><sup>2&nbsp; </sup>During the trial, randomised treatment was permanently discontinued by 16.7% and 18.6% of patients randomised to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed</p><p>Model for Repeated Measures including all observations until first discontinuation were -17.6% and -5.0% for semaglutide 2.4 mg and placebo respectively</p><p><sup>3&nbsp; </sup>Estimated from binary regression model based on same imputation procedure as in primary analysis.<sup> </sup>&nbsp;</p><p>&nbsp;</p><p><em><u>STEP 4: Sustained weight management</u> </em></p><p>In a 68-week double-blind trial, 902 patients with obesity (BMI &ge;30 kg/m<sup>2</sup>), or with overweight (BMI</p><p>&ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) and at least one weight-related comorbidity were included in the trial. All patients were on a reduced-calorie diet and increased physical activity throughout the trial. From week 0 to week 20 (run-in), all patients received semaglutide. At week 20 (baseline), patients who had reached the maintenance dose of 2.4 mg were randomised to continue treatment or switch to placebo. At week 0 (start of run-in period) patients had a mean body weight of 107.2 kg and a mean BMI of 38.4 kg/m<sup>2</sup>.</p><p>&nbsp;</p><p>Patients who had reached the maintenance dose of 2.4 mg at week 20 (baseline) and continued treatment with semaglutide for 48 weeks (week 20&ndash;68) continued losing weight and had a superior and clinically meaningful reduction in body weight compared to those switched to placebo (see Table 6 and Figure 3). The body weight increased steadily from week 20 to week 68 in patients switching to placebo at week 20 (baseline). Nevertheless, the observed mean body weight was lower at week 68 than at start of the run-in period (week 0) (see Figure 3). Patients treated with semaglutide from week</p><p>0 (run-in) to week 68 (end of treatment) achieved a mean change in body weight of 17.4%, with weight loss &ge;5% achieved by 87.8%, &ge;10% achieved by 78.0%, &ge;15% achieved by 62.2% and &ge;20% achieved by 38.6% of these patients.</p><p>&nbsp;</p><p>Table 6 STEP 4: Results from week 20 to week 68&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Wegovy </strong></p></td><td><p><strong>Placebo </strong></p></td></tr><tr><td><p>Full analysis set (N)</p></td><td><p>535</p></td><td><p>268</p></td></tr><tr><td><p><strong>Body weight </strong>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<sup>1</sup> (kg)<strong> </strong></p></td><td><p>96.5</p></td><td><p>95.4</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (%) from baseline<sup>1,2,3</sup><strong> </strong></p></td><td><p>-7.9</p></td><td><p>6.9</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (%) from placebo<sup>2</sup> [95% CI] <strong>&nbsp;</strong></p></td><td><p>-14.8 [-16.0; -13.5]*</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change (kg) from baseline</p></td><td><p>-7.1</p></td><td><p>6.1</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference (kg) from placebo<sup>2</sup> [95% CI]&nbsp;</p></td><td><p>-13.2 [-14.3; -12.0]</p></td><td><p>-</p></td></tr><tr><td><p><strong>Waist circumference (cm)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<strong> </strong></p></td><td><p>105.5</p></td><td><p>104.7</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1</sup><strong> </strong></p></td><td><p>-6.4</p></td><td><p>3.3</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>2</sup> [95% CI]<strong> </strong></p></td><td><p>&nbsp;-9.7 [-10.9; -8.5]*</p></td><td><p>-</p></td></tr><tr><td><p><strong>Systolic blood pressure<sub> </sub>(mmHg)</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Baseline<sup>1</sup></p></td><td><p>121</p></td><td><p>121</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Change from baseline<sup>1,2</sup></p></td><td><p>0.5</p></td><td><p>4.4</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp; Difference from placebo<sup>2 </sup>[95% CI]</p></td><td><p>-3.9 [-5.8; -2.0]*</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* p&lt;0.0001 (unadjusted 2-sided) for superiority,</p><p><sup>1&nbsp; </sup>Baseline = week 20</p><p><sup>2&nbsp; </sup>Estimated using an ANCOVA model using multiple imputation based on all data irrespective of discontinuation of randomised treatment or initiation of other anti-obesity medication or bariatric surgery.&nbsp;</p><p><sup>3&nbsp; </sup>During the trial, randomised treatment was permanently discontinued by 5.8% and 11.6% of patients randomized to semaglutide 2.4 mg and placebo, respectively. Assuming that all randomised patients stayed on treatment and did not receive additional anti-obesity therapies, the estimated changes from randomisation to week 68 for body weight based on a Mixed</p><p>Model for Repeated Measures including all observations until first discontinuation were -8.1% and 6.5% for semaglutide 2.4 mg and placebo respectively.</p><p><img alt="" width="428" height="280" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>Observed values for patients completing each scheduled visit, and estimates with multiple imputations (MI) from retrieved dropouts</p><p>Figure 3 STEP 4: Mean change in body weight (%) from week 0 to week 68</p><p>&nbsp;</p><p><em><u>Effect on body composition</u> </em></p><p>In a sub-study in STEP 1 (N = 140), body composition was measured using dual energy X-ray absorptiometry (DEXA). The results of the DEXA assessment showed that treatment with semaglutide was accompanied by greater reduction in fat mass than in lean body mass leading to an improvement in body composition compared to placebo after 68 weeks. Furthermore, this reduction in total fat mass was accompanied by a reduction in visceral fat. These results suggest that most of the total weight loss was attributable to a reduction in fat tissue, including visceral fat.</p><p><em><u>Improvement in physical functioning</u> </em></p><p>Semaglutide showed small improvements in physical functioning scores. Physical functioning was assessed using both the generic health-related quality of life questionnaire Short Form-36v2 Health Survey, Acute Version (SF-36) and the obesity-specific questionnaire Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT).</p><p><em>&nbsp;</em></p><p><em><u>Cardiovascular evaluation</u> </em></p><p>In the SUSTAIN 6 trial, 3,297 patients with insufficiently controlled type 2 diabetes and at high risk of cardiovascular events were randomised to semaglutide s.c. 0.5 mg or 1 mg once-weekly or placebo in addition to standard-of-care. The treatment duration was 104 weeks. The mean age was 65 years and the mean BMI was 33 kg/m<sup>2</sup>.&nbsp;</p><p>&nbsp;</p><p>The primary endpoint was the time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The total number of the MACE was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo.</p><p>&nbsp;</p><p>The cardiovascular safety of treatment with semaglutide 0.5 or 1 mg was confirmed as the hazard ratio (HR) for semaglutide vs. placebo was 0.74, [0.58, 0.95] [95% CI], driven by a decrease in the rate of non-fatal stroke and non-fatal myocardial infarction with no difference in cardiovascular death (see Figure 4).</p><p>&nbsp;</p><p><img alt="" width="391" height="280" src="data:image/png;base64,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" /></p><p>Figure 4: Kaplan-Maier plot of time to first occurrence of the composite outcome: Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (SUSTAIN 6)<strong> </strong></p><p>&nbsp;</p><p>Paediatric population</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Wegovy in one or more subsets of the paediatric population in the treatment of weight management (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compared to native GLP-1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration. The principal mechanism of protraction is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilised against degradation by the DPP-4 enzyme.</p><p>&nbsp;</p><p>Absorption</p><p>The average semaglutide steady state concentration following s.c. administration of the semaglutide maintenance dose was approximately 75 nmol/L in patients with overweight (BMI &ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) or obesity (BMI &ge; 30 kg/m<sup>2</sup>) based on data from phase 3a trials, where 90% of patients had average concentrations between 51 nmol/L and 110 nmol/L. Bioequivalence was established between exposure associated with semaglutide administered with the marketed drug product and the exposure obtained with the drug product used in phase 3a trials. The steady state exposure of semaglutide increased proportionally with doses from 0.25 mg up to 2.4 mg once weekly. Steady state exposure was stable with time as assessed up to week 68. Similar exposure was achieved with s.c. administration of semaglutide in the abdomen, thigh, or upper arm. The absolute bioavailability of semaglutide was 89%.</p><p>&nbsp;</p><p>Distribution</p><p>The mean volume of distribution of semaglutide following s.c. administration in patients with overweight or obesity was approximately 12.4 L. Semaglutide is extensively bound to plasma albumin (&gt;99%).</p><p>&nbsp;</p><p>Metabolism/biotransformation</p><p>Prior to excretion, semaglutide is extensively metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. The enzyme neutral endopeptidase (NEP) was identified as one of the active metabolic enzymes.</p><p>&nbsp;</p><p>Elimination</p><p>The primary excretion routes of semaglutide-related material are via the urine and faeces.</p><p>Approximately 3% of the absorbed dose was excreted in the urine as intact semaglutide.</p><p>The clearance of semaglutide in patients with overweight (BMI &ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) or obesity (BMI &ge;30 kg/m<sup>2</sup>) was approximately 0.05 L/h. With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for approximately 7 weeks after the last dose of 2.4 mg.</p><p>&nbsp;</p><p>Special populations</p><p><em><u>Elderly</u> </em></p><p>Age had no effect on the pharmacokinetics of semaglutide based on data from phase 3 trials including patients 18&ndash;86 years of age.</p><p>&nbsp;</p><p><em><u>Gender, race and ethnicity</u> </em></p><p>Gender, race (White, Black or African American, Asian) and ethnicity (Hispanic or Latino, nonHispanic or -Latino) had no effect on the pharmacokinetics of semaglutide based on data from phase 3a trials.</p><p>&nbsp;</p><p><em><u>Body weight</u> </em></p><p>Body weight had an effect on the exposure of semaglutide. Higher body weight was associated with lower exposure; a 20% difference in body weight between individuals will result in an approximate</p><p>18% difference in exposure. The 2.4 mg weekly dose of semaglutide provided adequate systemic exposures over the body weight range of 54.4&minus;245.6 kg evaluated for exposure response in the clinical trials<em>. </em></p><p>&nbsp;</p><p><em><u>Renal impairment</u> </em></p><p>Renal impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner. This was shown with a single dose of 0.5 mg semaglutide for patients with different degrees of renal impairment (mild, moderate, severe or patients in dialysis) compared with patients with normal renal function. This was also shown for patients with overweight (BMI &ge;27 kg/m<sup>2</sup> to &lt;30 kg/m<sup>2</sup>) or obesity (BMI &ge;30 kg/m<sup>2</sup>) and mild to moderate renal impairment based on data from phase 3a trials.</p><p><em><u>Hepatic impairment</u> </em></p><p>Hepatic impairment did not have any impact on the exposure of semaglutide. The pharmacokinetics of semaglutide were evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) and compared with patients with normal hepatic function in a study with a single dose of 0.5 mg semaglutide.</p><p>&nbsp;</p><p><em><u>Prediabetes and diabetes</u> </em></p><p>Prediabetes and diabetes did not have any clinically relevant effect on the exposure of semaglutide based on data from phase 3 trials.</p><p>&nbsp;</p><p><em><u>Immunogenicity</u> </em></p><p>Development of anti-semaglutide antibodies when treated with semaglutide occurred infrequently (see section 4.8) and the response did not appear to influence semaglutide pharmacokinetics.&nbsp;</p><p>&nbsp;</p><p><em><u>Paediatrics</u> </em></p><p>Safety and efficacy of semaglutide in children and adolescents below 18 years of age have not been studied.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity or genotoxicity.</p><p>&nbsp;</p><p>Non-lethal thyroid C-cell tumours observed in rodents are a class effect for GLP-1 receptor agonists. In 2-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumours at clinically relevant exposures. No other treatment-related tumours were observed. The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive. The relevance for humans is considered to be low, but cannot be completely excluded.</p><p>&nbsp;</p><p>In fertility studies in rats, semaglutide did not affect mating performance or male fertility. In female rats, an increase in oestrous cycle length and a small reduction in corpora lutea (ovulations) were observed at doses associated with maternal body weight loss.</p><p>&nbsp;</p><p>In embryo-foetal development studies in rats, semaglutide caused embryotoxicity below clinically relevant exposures. Semaglutide caused marked reductions in maternal body weight and reductions in embryonic survival and growth. In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. Mechanistic evaluations indicated that the embryotoxicity involved a GLP-1 receptor mediated impairment of the nutrient supply to the embryo across the rat yolk sac. Due to species differences in yolk sac anatomy and function, and due to lack of GLP-1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. However, a direct effect of semaglutide on the foetus cannot be excluded.</p><p>&nbsp;</p><p>In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown.</p><p>&nbsp;</p><p>Postnatal growth and development were evaluated in cynomolgus monkeys. Infants were slightly smaller at delivery but recovered during the lactation period.</p><p>&nbsp;</p><p>In juvenile rats, semaglutide caused delayed sexual maturation in both males and females. These delays had no impact upon fertility and reproductive capacity of either sex, or on the ability of the females to maintain pregnancy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-filled pen, single-use</p><p>Disodium phosphate, dihydrate</p><p>Sodium chloride</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p><p>&nbsp;</p><p>Pre-filled pen, FlexTouch</p><p>Disodium phosphate, dihydrate</p><p>Propylene glycerol</p><p>Phenol</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre-filled pen, single-use 
 
24 months. 
 
Wegovy may be stored unrefrigerated for up to 28 days at a temperature not above 30°C. Discard the pen if it has been out of the refrigerator for more than 28 days. 
 
Pre-filled pen, FlexTouch 
 
Before use: 3 years. 
After first use: 6 weeks. Store below 30°C or in a refrigerator (2°C to 8°C). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2 &deg;C-8 &deg;C). Keep away from the cooling element.&nbsp;</p><p>Do not freeze and do not use Wegovy if it has been frozen.</p><p>&nbsp;</p><p><u>Pre-filled pen, single use</u></p><p>Store the pen in the original carton in order to protect from light.&nbsp;</p><p>&nbsp;</p><p><u>Pre-filled pen, FlexTouch</u></p><p>After first use: Store below 30&deg;C or in a refrigerator (2&deg;C to 8&deg;C). Keep the pen cap on when the pen is not in use in order to protect it from light.</p><p>&nbsp;</p><p>Always remove the injection needle after each injection and store the pen without a needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled pen, single-use</u></p><p>1 mL glass syringe (type I glass) with attached stainless steel needle, rigid needle shield (type II/polyisoprene) and a rubber plunger (type I/chlorobutyl).</p><p>&nbsp;</p><p><u>Pre-filled pen, FlexTouch</u></p><p>1.5 mL or 3 mL glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted. The cartridge is assembled into a disposable pre-filled pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene.</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p>4 pre-filled single use pens</p><p>1 pre-filled pen (FlexTouch) and 4 disposable NovoFine Plus needles</p><p>3 pre-filled pens (FlexTouch) and 12 disposable NovoFine Plus needles</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre-filled pen, single-use</u></p><p>The pen is for single-use only.</p><p>&nbsp;</p><p><u>Pre-filled pen, FlexTouch</u></p><p>The patients should be advised to discard the injection needle in accordance with local requirements after each injection and store the Wegovy pen without an injection needle attached. This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing.</p><p>&nbsp;</p><p>The pen is for use by one person only.</p><p>&nbsp;</p><p>Wegovy can be administered with needles up to a length of 8 mm. The pen is designed to be used with NovoFine and NovoTwist<sup> </sup>disposable needles.</p><p>&nbsp;</p><p>Wegovy should not be used if it does not appear clear and colourless. The pen should not be used if it has been frozen.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé 
DK-2880 Bagsværd 
Denmark 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>